Related Experiment Videos
Dopamine and dobutamine in pediatric therapy.
1College of Pharmacy, Ohio State University, Columbus 43210.
Pharmacotherapy
|January 1, 1989
Summary
Dopamine and dobutamine are critical for treating pediatric shock and cardiac failure, with dose-dependent effects and varying pharmacokinetics in children. Neonatal responses differ due to developmental factors.
Area of Science:
- Pediatric Pharmacology
- Cardiovascular Therapeutics
Background:
- Dopamine hydrochloride is a key agent for managing shock and cardiac failure in pediatric patients.
- Its effects on blood pressure, cardiac output, and perfusion are dose-dependent and vary with age.
- Neonatal responses to dopamine are influenced by immature norepinephrine stores and autonomic nervous system development.
Purpose of the Study:
- To review the pharmacological effects, pharmacokinetics, and adverse responses of dopamine and dobutamine in pediatric populations.
- To highlight age-dependent variations in drug response and clearance, particularly in neonates.
- To compare the actions of dopamine and dobutamine, noting dobutamine's cardioselectivity and lack of dopaminergic effects.
Main Methods:
- Review of existing literature on dopamine and dobutamine use in neonates, infants, and children.
- Analysis of dose-dependent pharmacologic effects, including vascular resistance and myocardial contractility.
- Examination of pharmacokinetic data, focusing on elimination half-life and age-related clearance variations.
Main Results:
- Dopamine's effects range from vasodilation at low doses to increased vascular resistance at high doses, with diminished inotropic response in neonates.
- Dopamine clearance varies widely in pediatric patients; elimination half-life is longer in preterm infants.
- Dobutamine, a cardioselective beta-1 adrenergic agonist, increases cardiac output but lacks dopaminergic activity; its pharmacokinetics in neonates are not well-defined.
Conclusions:
- Dopamine and dobutamine are essential for pediatric circulatory support, but their use requires careful consideration of age-specific pharmacodynamics and pharmacokinetics.
- Neonates exhibit unique responses to dopamine due to developmental immaturity, potentially leading to adverse effects like tachycardia and arrhythmias at high doses.
- Further research is needed to elucidate dobutamine's pharmacokinetics in neonates and infants.